Mr Steven Zimmer

Founder and CEO

United Kingdom

Research Interests

Cancer, High Content in vitro screening, AI, Chemogenomics

We are using genomic signatures to filter and match drug combinations to a disease signature. To cali date these requires biomarkers and the best physiologically relevant model possible.